ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > IL-2 R beta & IL-2 R alpha & IL-2 R gamma

IL-2 R beta & IL-2 R alpha & IL-2 R gamma

概要

Name:Interleukin-2
Target Synonym:T-cell growth factor,IL2,Interleukin 2,T Cell Growth Factor,Aldesleukin,IL-2,TCGF,Involved In Regulation Of T-Cell Clonal Expansion,Interleukin-2,Lymphokine
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:31
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

ILG-C52W3-SPR
 IL-2 R beta & IL-2 R alpha & IL-2 R gamma SPR

Cynomolgus IL-2RB&IL-2RA&IL-2RG Protein, His Tag&Twin-Strep Tag (Cat. No. ILG-C52W3) captured on CM5 chip via anti-His antibody can bind Human IL-2, Tag Free with an affinity constant of 29.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

ILG-H52W9-SPR
 IL-2 R beta & IL-2 R alpha & IL-2 R gamma SPR

Human IL-2RB&IL-2RA&IL-2RG, His Tag&Twin Strep Tag (Cat. No. ILG-H52W9) captured on CM5 chip via anti-His antibody can bind Human IL-2, Tag Free with an affinity constant of 56.9 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).

IL-2 R beta & IL-2 R alpha & IL-2 R gamma Molecule Synonym Name

IL-2 R beta & IL-2 R alpha & IL-2 R gamma

IL-2 R beta & IL-2 R alpha & IL-2 R gamma Molecule Background

Both Interleukin-2 receptor subunit beta and Interleukin-2 receptor subunit gamma are receptor for interleukin-2. Common subunit for the receptors for a variety of interleukins. Interacts with SHB upon interleukin stimulation. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit.

IL-2 R beta & IL-2 R alpha & IL-2 R gamma References

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Thalidomide NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Mainland China Leprosy, Lepromatous; Multiple Myeloma Changzhou Pharmaceutical Factory 1982-01-01 Lymphoma, Mantle-Cell; Leprosy, Lepromatous; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Carcinoma, Adenosquamous; Cholangitis, Sclerosing; Osteosarcoma; Endometrial Neoplasms; Xerostomia; Gastrointestinal Hemorrhage; Sarcoma, Ewing; HIV Wasting Syndrome; Pancreatitis, Chronic; Arachnoiditis; Retinoblastoma; Erythema Nodosum; Prostatic Neoplasms; Drug Resistant Epilepsy; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Sarcoma; Angiodysplasia; Lymphoma, Non-Hodgkin; Appendiceal Neoplasms; Pelvic Pain; Waldenstrom Macroglobulinemia; Glioma; Uterine Neoplasms; Anemia, Sideroblastic; Lung Neoplasms; Mycobacterium Infections; Lupus Erythematosus, Discoid; Anemia, Refractory, with Excess of Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
DF-6215 DF6215; DF-6215 Phase 1 Clinical Dragonfly Therapeutics Llc Solid tumours Details
VIS171 VIS-171; VIS171 Phase 1 Clinical Visterra Inc Autoimmune Diseases Details
SHR-1916 SHR-1916 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours Details
RG-6279 RG-6279 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours Details
SAR-444336 SAR-444336 Phase 1 Clinical Sanofi Inflammation Details
STK-012 STK-012 Phase 1 Clinical Synthekine Inc Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
AB-248 AB-248 Phase 1 Clinical Asher Biotherapeutics Inc Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung Details
SIM-0278 ALM-223; SIM0278 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic Details
M5A-IL2 Immunocytokine M5A-ICK Phase 1 Clinical National Cancer Institute, City Of Hope National Medical Center Breast Neoplasms; Colorectal Neoplasms Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase 1 Clinical St Jude Children's Research Hospital, National Cancer Institute Neuroblastoma Details
Bifikafusp alfa L19-IL-2 Phase 3 Clinical Philogen Spa Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Igrelimogene litadenorepvec PM-1016; PM1016; TILT-123 Phase 1 Clinical Tilt Biotherapeutics Ltd Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular Details
attIL2-T cell therapy Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Soft Tissue Neoplasms; Osteosarcoma; Sarcoma Details
Dodekin Phase 1 Clinical Philogen Spa Solid tumours; Neoplasm Metastasis Details
T20K T-20K Phase 1 Clinical Cyxone Multiple Sclerosis Details
XTX-202 XTX-202 Phase 2 Clinical Xilio Development Inc, Xilio Therapeutics Inc Solid tumours; Carcinoma, Renal Cell; Melanoma Details
ASP-1012 VET2-L2; ASP-1012; ASP1012 Phase 1 Clinical KaliVir Immunotherapeutics Inc Solid tumours Details
AVB-001 AVB-001 Phase 2 Clinical Avenge Bio Inc Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
S-95007 S-95007 Phase 2 Clinical Laboratoires Servier Immune System Diseases; Inflammation Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase 3 Clinical Philogen Spa Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi Details
KB-707 KB-707; KB707 Phase 1 Clinical Krystal Biotech Inc Skin Melanoma; Carcinoma, Basal Cell; Neoplasms; Osteosarcoma; Carcinoma, Squamous Cell; Melanoma Details
Saltikva Phase 2 Clinical Salspera LLC Pancreatic Neoplasms Details
AU-007 BD-8; AU-007; BDG-8 Phase 2 Clinical Biolojic Design Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
KY-0118 KY-0118; KY0118 Phase 1 Clinical Novatim Immune Therapeutics (Zhejiang) Co Ltd Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
umitrelimorgene autodencel ITI-1000 Phase 2 Clinical Immunomic Therapeutics Inc Glioblastoma Details
MK-1484 MK-1484; SP-482 Phase 1 Clinical Merck & Co Inc, Sutro Biopharma Inc Solid tumours Details
BNT-153 BNT-153 Phase 1 Clinical Biontech Se Solid tumours Details
RS-2102 RS2102 Phase 1 Clinical Reistone Biopharma Co Ltd Dermatitis, Atopic Details
LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) Phase 2 Clinical Tcrcure Biopharma Ltd Nasopharyngeal Carcinoma Details
Mableukin 2PD1(Anwita Biosciences) AWT020; AWT-020 Phase 1 Clinical Anwita Biosciences Inc Neoplasms; Autoimmune Diseases of the Nervous System Details
BNZ-1 BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 Phase 2 Clinical Bioniz Therapeutics Inc Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic Details

This web search service is supported by Google Inc.

totopphone